Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419605 | 1.00 | EPHX2 (0.35) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3419209 | 1.00 | EPHX2 (0.35) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3414577 | 0.99 | EPHX2 (0.34) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3417853 | 0.95 | MEN1 (0.34) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3418673 | 0.91 | MEN1 (0.36) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3419498 | 0.87 | EPHX2 (0.36) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3419925 | 0.87 | EPHX2 (0.36) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3421637 | 0.87 | EPHX2 (0.36) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3418690 | 0.86 | EPHX2 (0.38) | EPHX2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3414590 | 0.86 | EPHX2 (0.36) | EPHX2MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | ARCN1, APP, ADAM17 | EPHX2 275/4885MEN1 3560/4885KMT2A 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.